Generic Drugs Will Dominate 70% Of The Market

- Aug 07, 2018 -

It also means a market battle between generics and generics, which the industry says seem to be winning.

On March 5, 2016, the general office of the state council issued the opinions on the consistent evaluation of the quality and efficacy of generic drugs, which is a guideline document for Chinese pharmaceutical enterprises to officially carry out the consistent evaluation of the quality and efficacy of generic drugs. Next, CFDA continuously improves the compliance evaluation rules.

At the end of 2017, the generic drug consistency evaluation released the first batch through the variety list, and the policies such as labeling, entering "orange peel book" and directly hanging the net were successively implemented.

In April 2018, China also issued opinions on the reform and improvement of generic drug supply security and use policy, which granted the same rights as the original research drug in terms of the payment standard of centralized purchasing, doctor's prescription and medical insurance through consistent evaluation. According to the industry, with the development of the pilot program of centralized procurement of drugs, a large number of imported original research drugs, especially imported ones with high prices after the patent period, will be replaced.

Industry analysis shows that in the future, generics (high imitation drugs) that have been developed and evaluated by consistency will account for at least 70% of the provincial market. However, under the "screening" of medical insurance payment standard, the cost performance of generic drugs is lower. Combined with the reform of medical insurance payment method under the prepayment of total amount, as well as the control pressure of medical institutions, it will become the first choice of medical institutions and clinicians to replace the original developed drugs in clinical practice.

Shanghai is undoubtedly a benchmark in the aspect of drug centralized bidding and procurement, and has always been supportive of the consistency evaluation of generic drugs.

Related News

Related Products

  • Ertapenem Sodium C22H24N3NaO7S
  • 4-nitrobenzyl-2-diazoacetoacetate 82551-63-1
  • 1,3-Dioxane-4,6-dione, 2,2-dimethyl
  • C6H8O4
  • Pharmaceutical Intermediate for Imipenem
  • DMSP